A-Alpha Bio a New York-based firm that characterizes protein-protein interactions raised $20 million in Series A funding.
Madrona Venture Group led the round, with additional participation from Perceptive Xontogeny Venture Fund and Lux Capital.
A-Alpha Bio uses the funding to build a new production laboratory, generate the largest-ever database of protein interaction measurements, and fill key roles in its organization. A-Alpha Bio also plans to expand its machine-learning capabilities to determine the rules of protein binding and enable in silico modeling of complex protein interaction networks.
Company: A-Alpha Bio, Inc.
Round: Series A
Funding Month: September 2021
Lead Investors: Madrona Venture Group
Additional Investors: Perceptive Xontogeny Venture Fund and Lux Capital
Company Website: http://aalphabio.com/
Software Category: Cell-based tools
About the Company: A-Alpha Bio provides cell-based tools for quantitative and high-throughput measurements of protein interactions, accelerating target discovery, library screening, and preclinical drug characterization. A-Alpha Bio's product, AlphaSeq, is a revolutionary cell-based platform technology that will fundamentally change the way that protein interactions are measured. A-Alpha Bio is a team of synthetic biologists, structural biologists, and next-generation sequencing experts who have come together to remove this industry-wide bottleneck.